Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGA007
- Development stage
- Preclinical
- Lead developer
- Biogenera
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
BGA007 is a preclinical-stage anti-gene peptide nucleic acid (Ag-PNA) oligonucleotide developed by Biogenera SpA that targets the Polo-like kinase 4 (PLK4) gene for the treatment of solid tumors and cancer. Utilizing the proprietary MyGenera platform, BGA007 is designed to bind directly to the PLK4 gene sequence within chromosomal DNA, blocking transcription and subsequent protein expression. PLK4 is a critical regulator of centriole duplication, and its overexpression is associated with genomic instability and tumorigenesis. By inhibiting PLK4 at the genomic level, BGA007 aims to provide a more potent and selective therapeutic approach compared to traditional antisense technologies that target mRNA.
- Other names
- PLK4-PNA anti-gene oligonucleotidePLK-4-PNA anti-gene oligonucleotidePLK 4-PNA anti-gene oligonucleotideAg-PNAPNA anti-gene oligonucleotide
02
Targets
PLK4 (Polo-like kinase 4)
Beyond the preview
Go deeper on BGA007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGA007.